Inspire Medical Systems gets green light for V
By HME News Staff
Updated 9:32 AM CDT, Mon August 5, 2024
MINNEAPOLIS – Inspire Medical Systems has announced approval from the U.S. Food and Drug Administration for the Inspire V therapy system, which includes a next generation neurostimulator for the treatment of obstructive sleep apnea. The system also includes the associated Bluetooth patient remote and physician programmer. “We are thrilled to announce the FDA approval of our next generation Inspire neurostimulation system,” said Tim Herbert, chairman and CEO of Inspire Medical Systems. “The FDA approval marks a key milestone for the future of Inspire therapy and reinforces the many years of hard work by our team members.” Inspire says its focus remains on operational readiness, which includes product manufacturing and establishing inventory levels to support a full commercial launch in the United States. The company continues to target a soft launch in late 2024 and a full launch in 2025.
Comments